Evidence map›Paper›PMID 27193130›Full record

Trial reportClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

Clinical and pathologic features of patients with non-epithelial ovarian cancer: retrospective analysis of a single institution 15-year experience.

E Kempf, G Desamericq, B Vieites, I Diaz-Padilla, E Calvo, P Estevez, A Garcia-Arreza, M A Martinez-Maestre, I Duran

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

E KempfMedical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain.
G DesamericqCentre de Référence Maladie de Huntington, AP-HP, Hôpital H. Mondor-A. Chenevier, Créteil, France.
B VieitesDepartment of Pathology, Hospital Universitario Virgen del Rocio, Seville, Spain.
I Diaz-PadillaDeanery of Doctorate Studies, School of Medicine, University of Seville, Seville, Spain.
E CalvoMedical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain.
P EstevezMedical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain.
A Garcia-ArrezaGynecology Department, Hospital Universitario Virgen del Rocio, Seville, Spain.
M A Martinez-MaestreGynecology Department, Hospital Universitario Virgen del Rocio, Seville, Spain.
I DuranMedical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain. ignacioduranmartinez@gmail.com.
Hospital Universitario Virgen del Rocío · ESHôpital Albert-Chenevier · FRInstituto de Biomedicina de Sevilla · ESUniversidad de Sevilla · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNon-epithelial ovarian cancers (NEOCs) are rare diseases. Despite their overall good prognosis, the best management and current prognostic factors remain unclear. The objective of our study was to assess the clinical and pathological features of NEOC patients treated in our institution in the last 15 years and to explore risk factors for relapse and survival. METHODS/PATIENTS: All patients with a pathological diagnosis of NEOC referred to the medical oncology department at Hospital Universitario Virgen del Rocio between 1999 and 2014 were included. Demographics, tumor characteristics, treatment procedures, and clinical follow-up were retrospectively collected. Risk factors for disease-free survival (DFS) and overall survival (OS) were assessed.

resultsFifty-seven patients were included, 33 (58 %) had a sex cord-stromal tumor (SCST) and 24 (42 %) had a germ-cell tumor (GCT). Median age, non-conservative surgery rates and DFS were lower in the GCT cohort; however, salvage chemotherapy led to a high proportion of complete responses in this group translating into a 90 % 3-year OS rate in both NEOC subtypes. The only identified risk factors statistically significant were stage and tumour relapse that associated, respectively, with DFS (HR = 8.84; 95 % CI 1.85-42) and OS (HR = 11.02; 95 % CI 1.76-68.7).

conclusionsDespite their rarity, NEOCs remain a highly curable group of neoplasm. In our series, a more conservative treatment approach in ovarian GCTs revealed comparable OS outcomes to SCST. No new risk factors that would help in patient stratification were identified.

Indexed as

AdultCombined Modality TherapyFemaleFollow-Up StudiesHumansLymphatic MetastasisMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasms, Germ Cell and EmbryonalNeoplasm StagingOvarian NeoplasmsPrognosisRetrospective StudiesRisk FactorsSurvival RateGerm-cell tumorsNon-epithelial ovarian cancerPrognostic factorsSex-cord stromal tumors

Identifiers

PMID27193130
OpenAlexW2403564219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.